We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Rita
Benabderrazik
r.benabderrazik@qmul.ac.uk
Dr
Alastair
Noyce
a.noyce@qmul.ac.uk
Dr
Alastair
Noyce
a.noyce@qmul.ac.uk
Ruby
Lathey
r.lathey@qmul.ac.uk
Extrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prospective pilot study of an online risk stratification algorithm which aims to identify groups at higher risk of Parkinson's disease. Over 1000 participants are being followed up longitudinally with annual assessments, with further tests for selected groups. New groups to be recruited to the study include those with unexplained smell loss, a sleep disturbance called RBD, and a group with idiopathic Parkinson's.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
a) Individuals with a diagnosis of atypical Parkinson's disease or Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PDÍľ drug induced PDÍľ corticobasal degeneration) b) Individuals with another neurological disorder including: dementia, movement disorders, stroke, motor neurone disease. c) Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrocloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Quetiapine, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Amiodarone, Bupropion, Cinnarizine, Diltiazem, Lithium, Methyldopa, Metoclopramide and Sodium Valproate)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Alastair
Noyce
a.noyce@qmul.ac.uk
Rita
Benabderrazik
r.benabderrazik@qmul.ac.uk
Dr
Alastair
Noyce
a.noyce@qmul.ac.uk
Ruby
Lathey
r.lathey@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 15582
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
